Bryan C Dickinson
Overview
Explore the profile of Bryan C Dickinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
3570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cao Y, Liu H, Lu S, Jones K, Govind A, Jeyifous O, et al.
Nat Commun
. 2023 Oct;
14(1):6827.
PMID: 37884512
Technologies capable of programmable translation activation offer strategies to develop therapeutics for diseases caused by insufficient gene expression. Here, we present "translation-activating RNAs" (taRNAs), a bifunctional RNA-based molecular technology that...
12.
Azizi S, Qiu T, Brookes N, Dickinson B
Cell Rep
. 2023 Sep;
42(9):113135.
PMID: 37715953
Extracellular signal-regulated kinases (ERK1/2) are key effector proteins of the mitogen-activated protein kinase pathway, choreographing essential processes of cellular physiology. Here, we discover that ERK1/2 are subject to S-acylation, a...
13.
Madugalle S, Liau W, Zhao Q, Li X, Gong H, Marshall P, et al.
J Neurosci
. 2023 Sep;
43(43):7084-7100.
PMID: 37669863
The RNA modification N-methyladenosine (mA) regulates the interaction between RNA and various RNA binding proteins within the nucleus and other subcellular compartments and has recently been shown to be involved...
14.
Chen L, Zhang L, Ye C, Zhou H, Liu B, Gao B, et al.
Cell Res
. 2023 Jun;
33(9):727-730.
PMID: 37316584
No abstract available.
15.
Martin N, Crupi M, Taha Z, Poutou J, Whelan J, Vallati S, et al.
Pharmaceuticals (Basel)
. 2023 May;
16(5).
PMID: 37242495
The approval of different cytokines as anti-neoplastic agents has been challenged by dose-limiting toxicities. Although reducing dose levels affords improved tolerability, efficacy is precluded at these suboptimal doses. Strategies combining...
16.
Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, et al.
Nat Commun
. 2023 May;
14(1):3035.
PMID: 37236967
The large coding potential of vaccinia virus (VV) vectors is a defining feature. However, limited regulatory switches are available to control viral replication as well as timing and dosing of...
17.
Wolf E, Lento C, Pu J, Dickinson B, Wilson D
Biochemistry
. 2023 May;
62(11):1619-1630.
PMID: 37192192
The structurally conserved B-cell lymphoma 2 (Bcl-2) family of protein function to promote or inhibit apoptosis through an exceedingly complex web of specific, intrafamilial protein-protein interactions. The critical role of...
18.
Abazari D, Wild A, Qiu T, Dickinson B, Bamji S
J Cell Sci
. 2023 Apr;
136(7).
PMID: 37039765
Activity-induced changes in protein palmitoylation can regulate the plasticity of synaptic connections, critically impacting learning and memory. Palmitoylation is a reversible post-translational modification regulated by both palmitoyl-acyl transferases that mediate...
19.
Dong G, Adak S, Spyropoulos G, Zhang Q, Feng C, Yin L, et al.
Cell Metab
. 2023 Jan;
35(2):332-344.e7.
PMID: 36634673
Hyperinsulinemia often precedes type 2 diabetes. Palmitoylation, implicated in exocytosis, is reversed by acyl-protein thioesterase 1 (APT1). APT1 biology was altered in pancreatic islets from humans with type 2 diabetes,...
20.
Brown R, Sharma A, Villanueva M, Li X, Onguka O, Zilbermintz L, et al.
Pathogens
. 2022 Nov;
11(11).
PMID: 36364996
Dynamic post-translational modifications allow the rapid, specific, and tunable regulation of protein functions in eukaryotic cells. -acylation is the only reversible lipid modification of proteins, in which a fatty acid,...